Free Trial
NASDAQ:ABEO

Abeona Therapeutics (ABEO) Stock Price, News & Analysis

Abeona Therapeutics logo
$5.41 +0.00 (+0.07%)
As of 12:59 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Abeona Therapeutics Stock (NASDAQ:ABEO)

Advanced

Key Stats

Today's Range
$5.29
$5.50
50-Day Range
$5.25
$7.23
52-Week Range
$3.93
$7.54
Volume
522,684 shs
Average Volume
1.00 million shs
Market Capitalization
$277.63 million
P/E Ratio
7.71
Dividend Yield
N/A
Price Target
$19.50
Consensus Rating
Moderate Buy

Company Overview

Abeona Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
86th Percentile Overall Score

ABEO MarketRank™: 

Abeona Therapeutics scored higher than 86% of companies evaluated by MarketBeat, and ranked 132nd out of 936 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Abeona Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 5 buy ratings, 1 hold rating, and no sell ratings.

  • Upside Potential

    Abeona Therapeutics has a consensus price target of $19.50, representing about 260.8% upside from its current price of $5.41.

  • Amount of Analyst Coverage

    Abeona Therapeutics has only been the subject of 3 research reports in the past 90 days.

  • Read more about Abeona Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Abeona Therapeutics are expected to decrease in the coming year, from ($1.16) to ($1.23) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Abeona Therapeutics is 7.72, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 82.56.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Abeona Therapeutics is 7.72, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 29.57.

  • Price to Book Value per Share Ratio

    Abeona Therapeutics has a P/B Ratio of 5.35. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Abeona Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    18.89% of the float of Abeona Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Abeona Therapeutics has a short interest ratio ("days to cover") of 10.6, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Abeona Therapeutics has recently decreased by 1.15%, indicating that investor sentiment is improving.
  • Dividend Yield

    Abeona Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Abeona Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    18.89% of the float of Abeona Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Abeona Therapeutics has a short interest ratio ("days to cover") of 10.6, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Abeona Therapeutics has recently decreased by 1.15%, indicating that investor sentiment is improving.
  • News Sentiment

    Abeona Therapeutics has a news sentiment score of 0.06. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.52 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 5 news articles for Abeona Therapeutics this week, compared to 4 articles on an average week.
  • Search Interest

    18 people have searched for ABEO on MarketBeat in the last 30 days. This is an increase of 1,700% compared to the previous 30 days.
  • MarketBeat Follows

    2 people have added Abeona Therapeutics to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Abeona Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $339,171.00 in company stock.

  • Percentage Held by Insiders

    Only 6.90% of the stock of Abeona Therapeutics is held by insiders.

  • Percentage Held by Institutions

    80.56% of the stock of Abeona Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Abeona Therapeutics' insider trading history.
Receive ABEO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Abeona Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ABEO Stock News Headlines

Brokerages Set Abeona Therapeutics Inc. (NASDAQ:ABEO) Price Target at $19.50
October 16 Changes the Microchip Game — and Investing
While everyone's chasing the same AI plays, George Gilder is focused on something completely different. He says a 4-nanometer device that's 80 MILLION times more powerful than the chip he gave Reagan is now being made in America for the first time. And he's identified 3 companies that control this technology.tc pixel
See More Headlines

ABEO Stock Analysis - Frequently Asked Questions

Abeona Therapeutics' stock was trading at $5.57 on January 1st, 2025. Since then, ABEO shares have decreased by 3.0% and is now trading at $5.4050.

Abeona Therapeutics Inc. (NASDAQ:ABEO) posted its quarterly earnings results on Thursday, August, 14th. The biopharmaceutical company reported $1.71 earnings per share for the quarter, topping analysts' consensus estimates of ($0.39) by $2.10. The biopharmaceutical company had revenue of $0.40 million for the quarter, compared to analyst estimates of $21.71 million.
Read the conference call transcript
.

Abeona Therapeutics shares reverse split on the morning of Tuesday, July 5th 2022.The 1-25 reverse split was announced on Tuesday, July 5th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, July 5th 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

Top institutional shareholders of Abeona Therapeutics include Simplify Asset Management Inc. (1.10%). Insiders that own company stock include Vishwas Seshadri, Joseph Walter Vazzano, Brendan M O'malley, Faith L Charles, Christine Berni Silverstein, Michael Amoroso, Leila Alland and Mark Alvino.
View institutional ownership trends
.

Shares of ABEO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Abeona Therapeutics investors own include Invesco QQQ (QQQ), NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Adobe (ADBE), CymaBay Therapeutics (CBAY) and GE Aerospace (GE).

Company Calendar

Last Earnings
8/14/2025
Today
10/23/2025
Next Earnings (Estimated)
11/13/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ABEO
Previous Symbol
OTCMKTS:ACCP
CIK
318306
Employees
90
Year Founded
2013

Price Target and Rating

High Price Target
$20.00
Low Price Target
$18.00
Potential Upside/Downside
+260.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.83
Research Coverage
6 Analysts

Profitability

EPS (Trailing Twelve Months)
$0.70
Trailing P/E Ratio
7.72
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$63.73 million
Net Margins
N/A
Pretax Margin
18,188.50%
Return on Equity
89.05%
Return on Assets
45.64%

Debt

Debt-to-Equity Ratio
0.09
Current Ratio
6.73
Quick Ratio
6.65

Sales & Book Value

Annual Sales
$3.50 million
Price / Sales
79.19
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.01 per share
Price / Book
5.35

Miscellaneous

Outstanding Shares
51,280,000
Free Float
47,741,000
Market Cap
$277.17 million
Optionable
Optionable
Beta
1.42

Social Links

Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

This page (NASDAQ:ABEO) was last updated on 10/23/2025 by MarketBeat.com Staff
From Our Partners